Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Esther Natalie Oliva has a total of 375 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Anemia and Patient‐Reported Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: A Real‐World Observational Study

    by Esther Natalie Oliva, Antonio M Risitano, Eros Di Bona, Alessandro Maria Vannucchi, Ilaria Maria Dellfino, Antonio De Vivo, Valentina Giai, Rosario Notaro, Giuseppe Iannì, Eloise Beggiato, et al.

    Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by complement‐mediated hemolysis, thrombosis, bone marrow failure, and anemia. Although current treatments improve outcomes, patients still experience hemolysis and could remain anemic with a negative impact on quality of life (QoL). The aim of this study was to assess whether patient‐reported outcomes (PROs) distinguish PNH patients with/without hemolysis and evaluate factors associated with PROs. Methods: In this international, multicenter, observational study, 97 PNH patients witfrom Italy and the UK completed the EORTC QLQ‐C30 and QLQ‐AA/PNH measures at baseline and after 2 weeks. Clinical, biochemical, and treatment data were collected. Hemolysis was defined as LDH ≥ 1.5 × upper normal limit. PRO scores were compared between patients above and below this threshold. Associations of PROs with patient and disease factors were analyzed. Results: Of 97 patients (mean age 49 ± 15), 24.7% were anemic (Hb < 10 g/dL) and 16% had hemolysis. QoL did not differ significantly by hemolysis status. However, anemia was associated with significantly lower EORTC QLQ‐C30 global health and functional scores ( p < 0.05), particularly in physical, role, and social domains, and with worse QLQ‐AA/PNH emotional, cognitive, and physical functioning, as well as greater illness intrusiveness and stigmatization. Fatigue, dyspnea, and pain were common symptoms in anemic patients. QLQ‐AA/PNH scores showed high internal consistency (Cronbach's α > 0.7) and test‐retest reliability (ICC: 0.72–0.95). Conclusions: Anemia, but not residual hemolysis, was associated with impaired QoL across multiple domains. Addressing anemia alongside hemolysis may improve PROs in the management of PNH. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission

  • Open Access

    Relationships Between Clinician-Patient Communication and the Quality of Life of Patients With Leukaemia: A Prospective Cross-Sectional Global Study

    by Samantha Nier, Alan J. Poots, Sarah Gunn, Esther Natalie Oliva, Tatyana Ionova, Sam Salek

    Introduction: This study examined relationships between patient reported quality of life and demographic, disease related, and clinician–patient communication variables in people with leukaemia, using a validated haematological malignancy specific patient-reported outcome measure to provide insights to help improve care and enhance patient well-being. Methods: A prospective global cross-sectional online questionnaire study was conducted, with people self-identifying as patients with leukaemia, that included 100 items on demographics, information on communication, disease and treatment and the Haematological Malignancy Patient-Reported Outcome (HM-PRO) instrument. The HM-PRO scores were analysed using Kruskal-Wallis tests and Gradient Boosting Decision Trees (GBDTs) to identify key factors associated with patient outcomes. Results: 2,260 patients with leukaemia participated, from 64 countries, of whom 1,993 completed the HM-PRO Part-A (measure of QoL) and 1,951 completed Part-B (signs and symptoms). The HM-PRO scores varied significantly by demographic factors, with younger patients (18–25) and people with acute leukaemia reporting the highest scores. Communication about treatment decisions and side effects was significantly associated with HM-PRO scores (η 2 : 0.012–0.063). GBDT models had high Area Under Curve but low accuracy: isolation and depression emerged as key predictors of QoL classification. Conclusion: Improved clinician-patient communication and psychosocial support may mitigate the burden of leukaemia. Tailored, person-centred approaches integrating medical and emotional care could improve QoL, treatment adherence, and outcomes, particularly for younger patients and people facing significant treatment challenges. However, given the cross-sectional design, causal inferences cannot be made. We note our findings are presented strictly as associations observed in cross-sectional data, and we acknowledge the potential for bidirectional relationships between QoL and the variables explored. The findings primarily reflect the experiences of individuals who are more engaged, digitally included, or connected to advocacy organisations, rather than the broader leukaemia population.

  • Open Access

    Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial

    by Mikkael A. Sekeres, Valeria Santini, Amer M. Zeidan, Uwe Platzbecker, Rami S. Komrokji, María Díez-Campelo, Pierre Fenaux, Michael R. Savona, Yazan F. Madanat, David Valcárcel, et al.

  • Open Access

    Use and reporting of patient-reported outcomes in randomized controlled trials in non-Hodgkin lymphoma: a scoping review

    by Julia Schroer, Paul Jan Bröckelmann, Sam Salek, Tatyana Ionova, Edward Laane, Esther Natalie Oliva, Ina Monsef, Nicole Skoetz, Mario Csenar

    Background: Non-Hodgkin lymphoma (NHL) constitutes a biologically and clinically heterogeneous group of lymphoid malignancies, with varying prognoses and treatment aims between indolent and aggressive subtypes. While survival outcomes remain key efficacy measures, they insufficiently capture the impact of disease and treatment on daily physical and psychosocial functioning, as well as quality of life (QoL). Objectives: To characterize the use and reporting of patient-reported outcomes (PROs) in adult NHL randomized controlled trials (RCTs), including the trajectory of PRO dissemination throughout the trial reporting process. Methods: MEDLINE, CENTRAL, ClinicalTrials.gov, and WHO ICTRP were systematically searched from 1 January 2017 to 19 January 2023 for NHL RCTs irrespective of subtype, with databases being re-searched until 4 February 2025. Cross-sectional and longitudinal descriptive analyses were conducted to investigate PRO use and reporting practices. Findings: 549 completed and ongoing RCTs met the eligibility criteria, of which 176 trials (32.1%) included a reference to PROs, and 27 (4.9%) used a PRO as a primary outcome. Overall, 95 PRO measures were identified across trials, with EORTC QLQ-C30, FACT-Lymphoma, and EQ-5D being referenced most frequently. Among trials with published results that pre-specified PROs, 25.0% entirely and 10.5% partly omitted PRO findings from their main full-texts, without addressing this shortcoming in subsequent publications. Conclusion: PROs are underused and underreported in RCTs in NHL. Standardized PRO evaluation methodology and guidance for the selection of fit-for-purpose PRO measures are needed, along with clear positioning of PROs alongside survival outcomes in clinical trial design and interpretation.


  • Open Access

    Sustained Erythroid Response to Eltrombopag in Low‐Risk Myelodysplastic Neoplasms With Severe Anemia and Thrombocytopenia: A Case Report

    by Ambra Di Veroli, Cinzia De Gregoris, Roberta Laureana, Matteo Caridi, Valentina Panichi, Monica Poscente, Esther Natalie Oliva, Roberto Latagliata

    Eltrombopag has been already employed for thrombocytopenia in myelodysplastic neoplasms (MDS), but its role and efficacy in improving other cytopenias are still unknown. In October 2020, a 58‐year‐old low‐risk MDS male with transfusion‐dependent/erythropoietin‐resistant anemia and severe thrombocytopenia (platelets [PLTs]: 19 × 10 9 /L) started eltrombopag in the EQOL‐MDS trial, showing an unexpected increase in Hb values up to 12.0 g/dL at Week 24, with discontinuation of the transfusion requirement. However, PLT levels remained unchanged and, as per protocol, eltrombopag was stopped in May 2021. After eltrombopag discontinuation, Hb levels worsened again with reappearance of transfusion requirement from July 2021. High‐dose erythropoietin and deferasirox (ferritin: 1140 ng/mL) were restarted in September 2021, without efficacy. Thus, in December 2022, eltrombopag was reinitiated on a compassionate basis, and a new progressive increase in Hb (also in PLT values) was observed. After 12 months of 2 nd eltrombopag treatment, Hb levels became normal, while PLT count maintained stable values of > 50 × 10 9 /L. At the last follow‐up, the patient was still in complete erythroid response (Hb > 12 g/dL) lasting > 29 months and in complete PLT response (> 100 × 10 9 /L) lasting > 18 months. Eltrombopag could be evaluated as a possible option for treatment of low‐risk MDS with anemia and thrombocytopenia.


  • Open Access

    Clinician’s knowledge and awareness of patient-reported outcomes in immune thrombocytopenia: Results of a national survey (ITP NET, GIMEMA Working Group Anemia and Thrombocytopenia)

    by Esther Natalie Oliva, Fabio Efficace, Maria Rosa Valvano, Paola Arcuri, Roberta Battistini, Elisa Buzzatti, Cristina Clissa, Cristina Danesin, Alessia Salemme, Francesco Sparano, et al.

    Background: Patient-reported outcomes (PROs) are increasingly recognized in hematology, yet clinician awareness remains limited. In immune thrombocytopenia (ITP), an autoimmune disease, symptoms like fatigue impact quality of life (QoL). Design and Methods: This Italian survey evaluated hematologists’ knowledge of PROs within the Italian ITP NET network. Between April 4–20, 2023, 63 hematologists from 49 centers were invited to complete a 63-item online questionnaire on demographics, QoL understanding, and attitudes toward clinical use. Results: Thirty-nine responded, treating a median of 50 ITP patients in the prior year. PROs were used in research by 51% and applied clinically by 56%. Greater PRO knowledge was found among hematologists with over 17 years’ experience (72%) and extensive ITP exposure (64%) (p=0.033 and p=0.037). Larger centers reported more trial involvement (p=0.035) and regular QoL tool use. Conclusion: Results highlight knowledge gaps and emphasize how clinical experience and exposure support effective PRO implementation in ITP.

  • Open Access

    Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers

    by Elena Crisà, Daniela Cilloni, Marta Riva, Enrico Balleari, Daniela Barraco, Beatrice Manghisi, Lorenza Borin, Michela Calmasini, Anna Calvisi, Isabella Capodanno, et al.

    Background/Objectives: The aim of this study was to assess the unmet needs of myelodysplastic neoplasm (MDS) patients and their caregivers, focusing on how these needs impact quality of life (QoL) and daily functioning. MDS predominantly affects older adults. It is often complicated by severe red blood cell transfusion-dependent anemia and may require frequent hospital visits, conferring a substantial burden on patients and caregivers. Methods: A national survey was conducted between June 2022 and May 2023 in 46 hematology centers across Italy, involving 259 patients and 105 caregivers. The survey included validated QoL tools (QOL-E and HM-PRO) to measure the impact of disease and treatments on health-related QoL and symptoms. Results: Of the 259 patients surveyed, 42% were transfusion-dependent, with 45% reporting distress related to hospital travel, which was significantly associated with lower QoL scores (QOL-E physical score 50.0 vs. 62.5, p < 0.001). Transfusion dependency led to worse outcomes across physical, emotional, and social domains (HM-PRO Part A score 59.8 vs. 23.7, p < 0.001). Anxiety affected 66% of patients, while 56% reported feeling emotionally distressed. Forty-eight percent of patients required a caregiver, and among caregivers, 29% reported significant disruption to their work, including changing their job or reduced hours. Patients requiring frequent hospital visits showed notably worse QoL scores (HM-PRO emotional score 56.8 vs. 31.8, p < 0.001). Conclusions: This study identified substantial unmet needs for MDS patients, particularly in addressing the heavy burden of transfusions and hospital visits. Both patients and caregivers experienced significant impact on daily life and on QoL, highlighting the urgent need for treatments that reduce hospital dependency, improve patient outcomes, and alleviate the caregiver burden.


  • Open Access

    Disease and treatment burden in patients with leukaemia: family members/partner perspective

    by Esther Natalie Oliva, Tatyana Ionova, Samantha Nier, Zack Pemberton-Whiteley, Nick York, Denis Costello, Sam Salek

    Background: Leukaemia patients require comprehensive care, including treatment, hospital visits, and family support. An awareness of the impact of leukaemia on family members is crucial. The Acute Leukemia Advocates Network, Chronic Lymphoid Leukemia (CLL) Advocates Network, and Chronic Myeloid Leukemia (CML) Advocates Network assessed the impact of leukaemia on patients and their families.Methods: A global anonymous online study ran from 18/09/21 to 07/01/2022, targeting leukaemia patients and their family members/partners. Demographic information, disease characteristics, treatment, and family members’ experience of caring for a relative with blood cancer were collected. Family members/partner assessed the disease impact on patients using the Hematological Malignancy-Patient Reported Outcome measure (HM-PRO) Part-A.Results: 571 family members/partners (70.9% female, aged 55 years) responded. They represented patients with CML (32.0%), CLL (26.3%), acute myeloid leukaemia (AML) (19.3%) acute lymphoblastic leukaemia (17.5%), and other leukaemias (4.9%). The majority (89.1%) lived with the patient, and 69.7% accompanied them to clinics. Daily support included household chores (60%), shopping (51.5%), transportation (37.1%), finances (28.9%), personal care (23.3%) and childcare (16.8%). About one-third (29.6%) felt that the diagnosis was insensitively conveyed and 81.3% sought prognosis information. Approximately 64% searched for alternative treatments. Approximately 40% of family members/partners (prevalently sons/daughters) expressed an impact on general quality of life, particularly on emotional behaviour and eating/drinking habits. The impact was greatest in family members representing patients aged <18 years with ALL and AML compared to CLL and CML.Conclusion: The burden on leukaemia patients’ family members is significant but often overlooked.


  • Open Access

    Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers

    by Elena Crisà, Daniela Cilloni, Marta Riva, Enrico Balleari, Daniela Barraco, Beatrice Manghisi, Lorenza Borin, Michela Calmasini, Anna Calvisi, Isabella Capodanno, et al.

    Background/Objectives: This study aimed to assess the unmet needs of myelodysplas-tic neoplasm (MDS) patients and their caregivers, focusing on how these needs impact quality of life (QoL) and daily functioning. MDS predominantly affects older adults. It is often complicated by severe red blood cell transfusion-dependent anemia and may require frequent hospital visits, conferring a substantial burden on patients and care-givers. Methods: A national survey was conducted between June 2022 and May 2023 in 46 hematology centers in Italy, involving 259 patients and 105 caregivers. The sur-vey included validated QoL tools (QOL-E and HM-PRO) to measure the impact of dis-ease and treatments on health-related (QoL) and symptoms. Results: Of the patients surveyed, 42% were transfusion-dependent, with 45% reporting distress related to hospital travel, which was significantly associated with lower QoL scores (QOL-E physical score 50.0 vs. 62.5, p<0.001). Transfusion dependency led to worse outcomes across physical, emotional, and social domains (HM-PRO part A score 59.8 vs 23.7, p<0.001). Anxiety affected 66% of patients, while 56% reported feeling emotionally distressed. Forty-eight percent of patients required a caregiver, and among the care-givers, 29% reported significant disruptions in their work, including job changes or reduced hours. Patients requiring frequent hospital visits showed notably worse QoL scores (HM-PRO emotional score 56.8 vs. 31.8, p<0.001). Conclusions: The study iden-tified substantial unmet needs for MDS patients, particularly in addressing the heavy burden of transfusions and hospital visits. Both patients and caregivers experienced significant impact on daily life and in QoL, underscoring the urgent need for treat-ments that reduce hospital dependency, improve patient outcomes, and alleviate the caregiver burden.